Form DEFA14A VERTEX PHARMACEUTICALS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/26/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
Truist Breaks Down The 'uptake and total addressable market of VRTX's NAV 1.8 pain drug VX-548'
April 5, 2024 1:46 PM EDTTruist Securities analyst Robyn Karnauskas reiterated a Buy rating and $508.00 price target on Vertex (NASDAQ: VRTX).
The analyst comments "We have been getting a lot of questions around uptake and total addressable market of VRTX's NAV 1.8 pain drug VX-548. We hosted renowned anesthesiologist Dr. Sabry Ayad and lay out the key takeaways from our call below. KOL was very encouraged to see a new class of drug showing great efficacy with good safety profile in phase 3... More
